Developer docs
API playgroundTry for free, no card

Search company profiles

Sapreme Technologies

Full company profile

uuid0002fr3

Namestring
Sapreme Technologies
Legal namestring
Sapreme Development B.V.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Sapreme Technologies (legally Sapreme Development B.V., rebranding to Sapreme Therapeutics B.V. effective June 1, 2026) is a preclinical-stage biotechnology company headquartered at Utrecht Science Park in the Netherlands. The company is developing next-generation RNA therapeutics for patients with genetically driven diseases, with a particular focus on neuromuscular conditions (notably Duchenne muscular dystrophy, the lead program positioned as a potential best-in-class therapy) and cardiometabolic diseases.

Sapreme's core asset is its proprietary endosomal escape technology platform, branded SPT, built around chemically modified glycosylated triterpenoids — plant secondary metabolites engineered to enhance intracellular delivery of large therapeutic molecules such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs). The technology is designed to remain inactive in circulation and, via a pH-driven mechanism, enable receptor-targeted release of therapeutic cargo from endosomes into the cytoplasm in liver and extrahepatic tissues including muscle, heart, and brain. The company cites proof-of-concept data in rodents and non-human primates.

As a preclinical company with no commercial products, Sapreme has not yet disclosed a pricing model or product revenue. Its commercial model is oriented toward strategic co-development partnerships with select pharma and biotech companies, supplemented by internal pipeline development. The company has raised $17 million in a Series A round (October 2021, Aglaia BioMedical Ventures), operates with 11-50 employees, and is led by CEO Marco Timmers (appointed May 2024) alongside founder/CSO Ruben Postel, with a Scientific Advisory Board covering RNA delivery and neuromuscular disease expertise.

Short descriptiontext

Sapreme Technologies is a preclinical-stage Dutch biotech developing a proprietary endosomal escape platform (SPT) to deliver RNA therapeutics (ASOs and siRNAs) to liver and extrahepatic tissues, with a lead program targeting Duchenne muscular dystrophy and a pipeline spanning neuromuscular and cardiometabolic diseases pursued via pharma partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersUtrecht, Netherlands
HQ citystring
Utrecht
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA therapeutics delivery, endosomal escape technology, oligonucleotide delivery platform, targeted intracellular delivery, genetic disease therapeutics
Industry3 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
Product category
RNA Therapeutics Delivery Technology
No data
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sapreme is a preclinical-stage biotechnology company developing a proprietary endosomal escape technology platform (SPT) that enables targeted intracellular delivery of large molecule RNA therapeutics such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs). The company is building a therapeutic pipeline anchored by a lead program designed as a best-in-class therapy for Duchenne muscular dystrophy, and pursues strategic co-development partnerships with pharma/biotech companies to advance its RNA therapeutics programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Less than 1% of next-generation therapeutics cross cellular barriers efficiently without technology enhancement
Product overview1 text field

Sapreme is a preclinical-stage biotech company developing a proprietary endosomal escape technology platform (SPT) for targeted delivery of RNA therapeutics. The SPT Platform enables delivery of large molecules such as ASOs and siRNAs to intracellular targets in liver and extrahepatic tissues including muscle, heart, and brain. The company is building a pipeline of therapeutic applications, with its lead program targeting Duchenne muscular dystrophy as a potential best-in-class therapy. The company pursues strategic partnerships with pharma/biotech companies for co-development of products.

Product and service2 records
1SPT Platform (Sapreme Technology Platform)
CategoryDrug Delivery Technology Platform
Description

Proprietary endosomal escape technology platform that enhances intracellular delivery of large molecule RNA therapeutics (ASOs and siRNAs) by mediating receptor-targeted delivery to endosomes and enabling pH-driven endosomal release. Used by Sapreme internally and offered to pharma/biotech partners through co-development arrangements to address the bottleneck of less than 1% of next-generation therapeutics crossing cellular barriers efficiently.

2Duchenne Muscular Dystrophy (DMD) Program
CategoryRNA Therapeutic (Preclinical)
Description

Sapreme's lead therapeutic program designed as a potential best-in-class therapy for Duchenne muscular dystrophy (DMD), an incurable and fatal pediatric monogenic disease. The program leverages the SPT endosomal escape technology platform to enable intracellular delivery of RNA-based therapeutics to muscle tissue.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Select pharma/biotech companies
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sapreme is pursuing strategic partnerships to co-develop products with select pharma/biotech companies. The company mentions they are building a pipeline of therapeutic applications and are open to co-development arrangements with industry partners to advance their RNA therapeutics programs.

sapreme.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing endosomal-escape-enabled therapeutics for DMD and other neuromuscular diseases; directly comparable to Sapreme's SPT approach with overlapping DMD lead program and shared mechanistic thesis on intracellular delivery.

TypeDirect peer
Description

Clinical-stage biotech with the FORCE platform delivering oligonucleotides to muscle, heart and CNS for DMD, DM1, and FSHD. Closely aligned target tissues and indication focus make it a strong direct peer for Sapreme's extrahepatic delivery strategy.

TypeBroad incumbent
Description

Commercial leader in siRNA therapeutics with the validated GalNAc liver-targeted delivery platform. Comparable as the dominant incumbent in oligonucleotide delivery, though Sapreme's extrahepatic focus and endosomal-escape mechanism differentiate Sapreme's niche.

TypeDirect peer
Description

Develops RNAi therapeutics with the TRiM platform targeting multiple tissues including muscle and CNS, directly competing in extrahepatic oligonucleotide delivery and DMD-adjacent indications.

TypeDirect peer
Description

Established antisense oligonucleotide (ASO) leader with multiple approved and clinical-stage programs. Highly comparable as a primary ASO developer that could be a customer or competitor for Sapreme's delivery technology.

TypeDirect peer
Description

Commercial-stage leader in DMD therapeutics using PMO ASOs (eteplirsen, golodirsen, casimersen). Directly comparable target indication and oligonucleotide modality, representing the benchmark Sapreme's lead program aims to surpass.

TypeEmerging player
Description

Clinical-stage company developing cell-penetrating peptide-conjugated oligonucleotides for DMD and DM1. Comparable target indications and delivery-enhancement thesis, though PepGen uses peptide rather than triterpenoid chemistry.

TypeEmerging player
Description

Clinical-stage company developing antibody-RNA conjugates (AOCs) for muscle and rare diseases, including DMD. Overlapping extrahepatic-delivery thesis and oligonucleotide payload focus make it a relevant emerging peer.

TypeDirect peer
Description

Develops stereopure oligonucleotide therapeutics using the PRISM platform across multiple tissues including muscle and CNS, including DMD programs. Directly comparable as a next-generation oligonucleotide developer with chemical-modification differentiation.

TypeEmerging player
Description

Develops lipid nanoparticle (LNP) and other delivery technologies for RNA therapeutics, including extrahepatic applications. Comparable as a delivery-platform peer addressing the same intracellular-delivery bottleneck Sapreme targets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sapreme Technologies

RNA Therapeutics Delivery Technologysapreme-technologies.com

Sapreme Technologies is a preclinical-stage Dutch biotech developing a proprietary endosomal escape platform (SPT) to deliver RNA therapeutics (ASOs and siRNAs) to liver and extrahepatic tissues, with a lead program targeting Duchenne muscular dystrophy and a pipeline spanning neuromuscular and cardiometabolic diseases pursued via pharma partnerships.

What Sapreme Technologies does

Sapreme Technologies (legally Sapreme Development B.V., rebranding to Sapreme Therapeutics B.V. effective June 1, 2026) is a preclinical-stage biotechnology company headquartered at Utrecht Science Park in the Netherlands. The company is developing next-generation RNA therapeutics for patients with genetically driven diseases, with a particular focus on neuromuscular conditions (notably Duchenne muscular dystrophy, the lead program positioned as a potential best-in-class therapy) and cardiometabolic diseases.

Sapreme's core asset is its proprietary endosomal escape technology platform, branded SPT, built around chemically modified glycosylated triterpenoids — plant secondary metabolites engineered to enhance intracellular delivery of large therapeutic molecules such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs). The technology is designed to remain inactive in circulation and, via a pH-driven mechanism, enable receptor-targeted release of therapeutic cargo from endosomes into the cytoplasm in liver and extrahepatic tissues including muscle, heart, and brain. The company cites proof-of-concept data in rodents and non-human primates.

As a preclinical company with no commercial products, Sapreme has not yet disclosed a pricing model or product revenue. Its commercial model is oriented toward strategic co-development partnerships with select pharma and biotech companies, supplemented by internal pipeline development. The company has raised $17 million in a Series A round (October 2021, Aglaia BioMedical Ventures), operates with 11-50 employees, and is led by CEO Marco Timmers (appointed May 2024) alongside founder/CSO Ruben Postel, with a Scientific Advisory Board covering RNA delivery and neuromuscular disease expertise.

Sapreme Technologies firmographics

Firmographics
Name
Sapreme Technologies
Legal name
Sapreme Development B.V.
Website
https://sapreme-technologies.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Sapreme Technologies is a preclinical-stage Dutch biotech developing a proprietary endosomal escape platform (SPT) to deliver RNA therapeutics (ASOs and siRNAs) to liver and extrahepatic tissues, with a lead program targeting Duchenne muscular dystrophy and a pipeline spanning neuromuscular and cardiometabolic diseases pursued via pharma partnerships.
Ownership category
akta.pro rank

Sapreme Technologies industry classification

Industry
Product category
RNA Therapeutics Delivery Technology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNA therapeutics delivery
  • Endosomal escape technology
  • Oligonucleotide delivery platform
  • Targeted intracellular delivery
  • Genetic disease therapeutics

Where Sapreme Technologies is headquartered

Location

Headquarters

HQ city
Utrecht
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Sapreme Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Sapreme Technologies product offering

Product offering

Core offering

Sapreme is a preclinical-stage biotechnology company developing a proprietary endosomal escape technology platform (SPT) that enables targeted intracellular delivery of large molecule RNA therapeutics such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs). The company is building a therapeutic pipeline anchored by a lead program designed as a best-in-class therapy for Duchenne muscular dystrophy, and pursues strategic co-development partnerships with pharma/biotech companies to advance its RNA therapeutics programs.

Product overview

Sapreme is a preclinical-stage biotech company developing a proprietary endosomal escape technology platform (SPT) for targeted delivery of RNA therapeutics. The SPT Platform enables delivery of large molecules such as ASOs and siRNAs to intracellular targets in liver and extrahepatic tissues including muscle, heart, and brain. The company is building a pipeline of therapeutic applications, with its lead program targeting Duchenne muscular dystrophy as a potential best-in-class therapy. The company pursues strategic partnerships with pharma/biotech companies for co-development of products.

Differentiator

Problem solved

Functional benefit

Products and services

  • SPT Platform (Sapreme Technology Platform) Proprietary endosomal escape technology platform that enhances intracellular delivery of large molecule RNA therapeutics (ASOs and siRNAs) by mediating receptor-targeted delivery to endosomes and enabling pH-driven endosomal release. Used by Sapreme internally and offered to pharma/biotech partners through co-development arrangements to address the bottleneck of less than 1% of next-generation therapeutics crossing cellular barriers efficiently.
  • Duchenne Muscular Dystrophy (DMD) Program Sapreme's lead therapeutic program designed as a potential best-in-class therapy for Duchenne muscular dystrophy (DMD), an incurable and fatal pediatric monogenic disease. The program leverages the SPT endosomal escape technology platform to enable intracellular delivery of RNA-based therapeutics to muscle tissue.

Quantifiable outcome

  • Less than 1% of next-generation therapeutics cross cellular barriers efficiently without technology enhancement

Companies that use Sapreme Technologies

Customer profile

Segments1 record

Ideal customer profiles1 record

Sapreme Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Sapreme Technologies partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Select pharma/biotech companiescoreStrategic or Co-development PartnerSapreme is pursuing strategic partnerships to co-develop products with select pharma/biotech companies. The company mentions they are building a pipeline of therapeutic applications and are open to co-development arrangements with industry partners to advance their RNA therapeutics programs.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Sapreme Technologies competitors and assessment

Company assessment

Direct peers

  • Entrada Therapeutics: Clinical-stage biotech developing endosomal-escape-enabled therapeutics for DMD and other neuromuscular diseases; directly comparable to Sapreme's SPT approach with overlapping DMD lead program and shared mechanistic thesis on intracellular delivery.
  • Dyne Therapeutics: Clinical-stage biotech with the FORCE platform delivering oligonucleotides to muscle, heart and CNS for DMD, DM1, and FSHD. Closely aligned target tissues and indication focus make it a strong direct peer for Sapreme's extrahepatic delivery strategy.
  • Arrowhead Pharmaceuticals: Develops RNAi therapeutics with the TRiM platform targeting multiple tissues including muscle and CNS, directly competing in extrahepatic oligonucleotide delivery and DMD-adjacent indications.
  • Ionis Pharmaceuticals: Established antisense oligonucleotide (ASO) leader with multiple approved and clinical-stage programs. Highly comparable as a primary ASO developer that could be a customer or competitor for Sapreme's delivery technology.
  • Sarepta Therapeutics: Commercial-stage leader in DMD therapeutics using PMO ASOs (eteplirsen, golodirsen, casimersen). Directly comparable target indication and oligonucleotide modality, representing the benchmark Sapreme's lead program aims to surpass.
  • Wave Life Sciences: Develops stereopure oligonucleotide therapeutics using the PRISM platform across multiple tissues including muscle and CNS, including DMD programs. Directly comparable as a next-generation oligonucleotide developer with chemical-modification differentiation.

Broad incumbents

  • Alnylam Pharmaceuticals: Commercial leader in siRNA therapeutics with the validated GalNAc liver-targeted delivery platform. Comparable as the dominant incumbent in oligonucleotide delivery, though Sapreme's extrahepatic focus and endosomal-escape mechanism differentiate Sapreme's niche.

Emerging players

  • PepGen: Clinical-stage company developing cell-penetrating peptide-conjugated oligonucleotides for DMD and DM1. Comparable target indications and delivery-enhancement thesis, though PepGen uses peptide rather than triterpenoid chemistry.
  • Avidity Biosciences: Clinical-stage company developing antibody-RNA conjugates (AOCs) for muscle and rare diseases, including DMD. Overlapping extrahepatic-delivery thesis and oligonucleotide payload focus make it a relevant emerging peer.
  • Genevant Sciences: Develops lipid nanoparticle (LNP) and other delivery technologies for RNA therapeutics, including extrahepatic applications. Comparable as a delivery-platform peer addressing the same intracellular-delivery bottleneck Sapreme targets.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Sapreme Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sapreme Technologies leadership team

Management profile

Number of profiles

Profiles13 records

Sapreme Technologies funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sapreme Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sapreme Technologies

What does Sapreme Technologies do?

Sapreme is a preclinical-stage biotechnology company developing a proprietary endosomal escape technology platform (SPT) that enables targeted intracellular delivery of large molecule RNA therapeutics such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs). The company is building a therapeutic pipeline anchored by a lead program designed as a best-in-class therapy for Duchenne muscular dystrophy, and pursues strategic co-development partnerships with pharma/biotech companies to advance its RNA therapeutics programs.

Is Sapreme Technologies a public or private company?

Sapreme Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sapreme Technologies founded?

Sapreme Technologies was founded in 2016. It employs 11 to 50 people.

Where is Sapreme Technologies based?

Sapreme Technologies is headquartered in Utrecht, Netherlands, in the Europe region.

Who are Sapreme Technologies's main competitors?

Direct peers on record are Entrada Therapeutics, Dyne Therapeutics, Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Sarepta Therapeutics and Wave Life Sciences. Alnylam Pharmaceuticals is listed as a broad incumbent. Emerging players are PepGen, Avidity Biosciences and Genevant Sciences.

Does Sapreme Technologies have an API?

No public API is recorded for Sapreme Technologies.

What industry is Sapreme Technologies in?

Sapreme Technologies's product category is RNA Therapeutics Delivery Technology. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 541714 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireSapreme Therapeutics announces oral presentation of new preclinical data on lead Duchenne muscular dystrophy candidate SPM-2551 at OTS 2026Sapreme Therapeutics announced new preclinical data for its lead Duchenne muscular dystrophy candidate, SPM-2551, to be presented at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society in Denver. The data demonstrated that the drug restored dystrophin levels significantly higher than comparators using much lower doses by utilizing a proprietary platform that overcomes endosomal entrapment. These findings support the company's plan to advance SPM-2551 toward IND-enabling studies in 2027.European UnionENDOSCAPE, a clinically applicable non-viral gene delivery technologyThe article lists participants in the HORIZON collaboration network project titled 'ENDOSCAPE, a clinically applicable non-viral gene delivery technology,' detailing their respective net EU financial contributions and total costs. Key participants include SAPREME TECHNOLOGIES BV, MAX-PLANCK-GESELLSCHAFT, VIB, and EXTRASYNTHESE SAS, among several universities and research institutes across Europe. The data outlines the specific funding allocations for each organization involved in this EU R&I programme.FinSMEsSapreme Technologies in €6.8M EU AllianceSapreme Technologies, a Dutch biotech, received a 6.8M€ EU Horizon 2020 grant with a consortium of 11 partners to develop non-viral gene therapy. The grant funds work on its proprietary endosomal escape enhancers to improve drug delivery for macromolecule therapeutics.